1. Market Research
  2. > Bacterial Infections – Pipeline Review, H1 2013

Bacterial Infections – Pipeline Review, H1 2013

  • June 2013
  • -
  • Global Markets Direct
  • -
  • 499 pages

Bacterial Infections – Pipeline Review, H1 2013

Summary

Global Markets Direct’s, 'Bacterial Infections - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Bacterial Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Bacterial Infections. Bacterial Infections - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Bacterial Infections.
- A review of the Bacterial Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Bacterial Infections pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Bacterial Infections.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Bacterial Infections pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Bacterial Infections - Pipeline Review, H1 2013
Table of Contents
Table of Contents 2
Introduction 12
Bacterial Infections Overview 13
Therapeutics Development 14
Bacterial Infections Therapeutics under Development by Companies 16
Bacterial Infections Therapeutics under Investigation by Universities/Institutes 39
Late Stage Products 46
Mid Clinical Stage Products 47
Early Clinical Stage Products 48
Discovery and Pre-Clinical Stage Products 49
Bacterial Infections Therapeutics - Products under Development by Companies 50
Bacterial Infections Therapeutics - Products under Investigation by Universities/Institutes 93
Companies Involved in Bacterial Infections Therapeutics Development 102
Bacterial Infections - Therapeutics Assessment 344
Drug Profiles 350
Bacterial Infections Therapeutics - Drug Profile Updates 415
Bacterial Infections Therapeutics - Discontinued Products 444
Bacterial Infections Therapeutics - Dormant Products 453
Bacterial Infections - Product Development Milestones 481
Appendix 488

List of Tables

Number of Products Under Development for Bacterial Infections, H1 2013 24
Products under Development for Bacterial Infections - Comparative Analysis, H1 2013 25
Number of Products under Development by Companies, H1 2013 27
Number of Products under Development by Companies, H1 2013 (Contd..1) 28
Number of Products under Development by Companies, H1 2013 (Contd..2) 29
Number of Products under Development by Companies, H1 2013 (Contd..3) 30
Number of Products under Development by Companies, H1 2013 (Contd..4) 31
Number of Products under Development by Companies, H1 2013 (Contd..5) 32
Number of Products under Development by Companies, H1 2013 (Contd..6) 33
Number of Products under Development by Companies, H1 2013 (Contd..7) 34
Number of Products under Development by Companies, H1 2013 (Contd..8) 35
Number of Products under Development by Companies, H1 2013 (Contd..9) 36
Number of Products under Development by Companies, H1 2013 (Contd..10) 37
Number of Products under Development by Companies, H1 2013 (Contd..11) 38
Number of Products under Development by Companies, H1 2013 (Contd..12) 39
Number of Products under Development by Companies, H1 2013 (Contd..13) 40
Number of Products under Development by Companies, H1 2013 (Contd..14) 41
Number of Products under Development by Companies, H1 2013 (Contd..15) 42
Number of Products under Development by Companies, H1 2013 (Contd..16) 43
Number of Products under Development by Companies, H1 2013 (Contd..17) 44
Number of Products under Development by Companies, H1 2013 (Contd..18) 45
Number of Products under Development by Companies, H1 2013 (Contd..19) 46
Number of Products under Development by Companies, H1 2013 (Contd..20) 47
Number of Products under Development by Companies, H1 2013 (Contd..21) 48
Number of Products under Investigation by Universities/Institutes, H1 2013 50
Number of Products under Investigation by Universities/Institutes, H1 2013 (Contd..1) 51
Number of Products under Investigation by Universities/Institutes, H1 2013 (Contd..2) 52
Number of Products under Investigation by Universities/Institutes, H1 2013 (Contd..3) 53
Number of Products under Investigation by Universities/Institutes, H1 2013 (Contd..4) 54
Number of Products under Investigation by Universities/Institutes, H1 2013 (Contd..5) 55
Comparative Analysis by Late Stage Development, H1 2013 56
Comparative Analysis by Mid Clinical Stage Development, H1 2013 57
Comparative Analysis by Early Clinical Stage Development, H1 2013 58
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2013 59
Products under Development by Companies, H1 2013 60
Products under Development by Companies, H1 2013 (Contd..1) 61
Products under Development by Companies, H1 2013 (Contd..2) 62
Products under Development by Companies, H1 2013 (Contd..3) 63
Products under Development by Companies, H1 2013 (Contd..4) 64
Products under Development by Companies, H1 2013 (Contd..5) 65
Products under Development by Companies, H1 2013 (Contd..6) 66
Products under Development by Companies, H1 2013 (Contd..7) 67
Products under Development by Companies, H1 2013 (Contd..8) 68
Products under Development by Companies, H1 2013 (Contd..9) 69
Products under Development by Companies, H1 2013 (Contd..10) 70
Products under Development by Companies, H1 2013 (Contd..11) 71
Products under Development by Companies, H1 2013 (Contd..12) 72
Products under Development by Companies, H1 2013 (Contd..13) 73
Products under Development by Companies, H1 2013 (Contd..14) 74
Products under Development by Companies, H1 2013 (Contd..15) 75
Products under Development by Companies, H1 2013 (Contd..16) 76
Products under Development by Companies, H1 2013 (Contd..17) 77
Products under Development by Companies, H1 2013 (Contd..18) 78
Products under Development by Companies, H1 2013 (Contd..19) 79
Products under Development by Companies, H1 2013 (Contd..20) 80
Products under Development by Companies, H1 2013 (Contd..21) 81
Products under Development by Companies, H1 2013 (Contd..22) 82
Products under Development by Companies, H1 2013 (Contd..23) 83
Products under Development by Companies, H1 2013 (Contd..24) 84
Products under Development by Companies, H1 2013 (Contd..25) 85
Products under Development by Companies, H1 2013 (Contd..26) 86
Products under Development by Companies, H1 2013 (Contd..27) 87
Products under Development by Companies, H1 2013 (Contd..28) 88
Products under Development by Companies, H1 2013 (Contd..29) 89
Products under Development by Companies, H1 2013 (Contd..30) 90
Products under Development by Companies, H1 2013 (Contd..31) 91
Products under Development by Companies, H1 2013 (Contd..32) 92
Products under Development by Companies, H1 2013 (Contd..33) 93
Products under Development by Companies, H1 2013 (Contd..34) 94
Products under Development by Companies, H1 2013 (Contd..35) 95
Products under Development by Companies, H1 2013 (Contd..36) 96
Products under Development by Companies, H1 2013 (Contd..37) 97
Products under Development by Companies, H1 2013 (Contd..38) 98
Products under Development by Companies, H1 2013 (Contd..39) 99
Products under Development by Companies, H1 2013 (Contd..40) 100
Products under Development by Companies, H1 2013 (Contd..41) 101
Products under Development by Companies, H1 2013 (Contd..42) 102
Products under Investigation by Universities/Institutes, H1 2013 103
Products under Investigation by Universities/Institutes, H1 2013 (Contd..1) 104
Products under Investigation by Universities/Institutes, H1 2013 (Contd..2) 105
Products under Investigation by Universities/Institutes, H1 2013 (Contd..3) 106
Products under Investigation by Universities/Institutes, H1 2013 (Contd..4) 107
Products under Investigation by Universities/Institutes, H1 2013 (Contd..5) 108
Products under Investigation by Universities/Institutes, H1 2013 (Contd..6) 109
Products under Investigation by Universities/Institutes, H1 2013 (Contd..7) 110
Products under Investigation by Universities/Institutes, H1 2013 (Contd..8) 111
Bristol-Myers Squibb Company, H1 2013 112
Baxter International Inc., H1 2013 113
Johnson and Johnson, H1 2013 114
Aradigm Corporation, H1 2013 115
Sequella, Inc., H1 2013 116
Shionogi and Co., Ltd., H1 2013 117
Sanofi-Aventis, H1 2013 118
AstraZeneca PLC, H1 2013 119
Eli Lilly and Company, H1 2013 120
GlaxoSmithKline plc, H1 2013 121
Genentech, Inc., H1 2013 122
Nektar Therapeutics, H1 2013 123
Bavarian Nordic A/S, H1 2013 124
MedImmune LLC, H1 2013 125
Daiichi Sankyo Company, Ltd, H1 2013 126
Targeted Genetics Corporation, H1 2013 127
Medicis Pharmaceutical Corporation, H1 2013 128
Merck and Co., Inc., H1 2013 129
Dainippon Sumitomo Pharma Co., Ltd., H1 2013 130
Taisho Pharmaceutical Co., Ltd., H1 2013 131
Emergent BioSolutions Inc., H1 2013 132
Cangene Corporation, H1 2013 133
ACE BioSciences A/S, H1 2013 134
Cytokine PharmaSciences, Inc., H1 2013 135
Takeda Pharmaceutical Company Limited, H1 2013 136
BioLineRx, Ltd., H1 2013 137
Symphogen A/S, H1 2013 138
Piramal Healthcare Limited, H1 2013 139
Nanotherapeutics, Inc., H1 2013 140
Biological E. Limited, H1 2013 141
Rib-X Pharmaceuticals, Inc., H1 2013 142
Novartis AG, H1 2013 143
Aphios Corporation, H1 2013 144
Achillion Pharmaceuticals, Inc., H1 2013 145
Actelion Ltd, H1 2013 146
Axcan Pharma Inc., H1 2013 147
BioMarin Pharmaceutical Inc., H1 2013 148
Chiesi Farmaceutici SpA, H1 2013 149
Cubist Pharmaceuticals, Inc., H1 2013 150
Dr. Reddy's Laboratories Limited, H1 2013 151
Ildong Pharmaceutical Co., Ltd., H1 2013 152
Nippon Shinyaku Co., Ltd., H1 2013 153
Pfizer Inc., H1 2013 154
Vertex Pharmaceuticals Incorporated, H1 2013 155
ViroPharma Incorporated, H1 2013 156
Wockhardt Limited, H1 2013 157
Hadasit Medical Research Services and Development Ltd, H1 2013 158
Venus Remedies Limited, H1 2013 159
Aduro BioTech, H1 2013 160
Optimer Pharmaceuticals, Inc., H1 2013 161
Paratek Pharmaceuticals, Inc., H1 2013 162
CEL-SCI Corporation, H1 2013 163
AVI BioPharma Inc., H1 2013 164
Crucell N.V., H1 2013 165
PARI Pharma GmbH, H1 2013 166
Zosano Pharma, Inc., H1 2013 167
Trinity Biosystems, Inc., H1 2013 168
Alchemia Limited, H1 2013 169
Affinium Pharmaceuticals, Inc., H1 2013 170
Helix BioMedix, Inc., H1 2013 171
Hollis-Eden Pharmaceuticals, Inc., H1 2013 172
Immtech Pharmaceuticals, Inc., H1 2013 173
Insmed Incorporated, H1 2013 174
Intercell AG, H1 2013 175
Lorus Therapeutics Inc, H1 2013 176
Basilea Pharmaceutica Ltd., H1 2013 177
MethylGene Inc, H1 2013 178
BioDiem Ltd, H1 2013 179
NovaBay Pharmaceuticals, Inc., H1 2013 180
Columbia Laboratories Inc., H1 2013 181
Nymox Pharmaceutical Corporation, H1 2013 182
Oragenics, Inc., H1 2013 183
Orchid Chemicals and Pharmaceuticals Ltd, H1 2013 184
Patrys Limited, H1 2013 185
Pevion Biotech Ltd, H1 2013 186
PharmAthene, Inc., H1 2013 187
Soligenix, Inc., H1 2013 188
SIGA Technologies, Inc., H1 2013 189
Elusys Therapeutics, Inc., H1 2013 190
Thallion Pharmaceuticals Inc., H1 2013 191
XOMA Ltd., H1 2013 192
MorphoSys AG, H1 2013 193
Starpharma Holdings Limited, H1 2013 194
Transgene SA, H1 2013 195
Immuron Limited, H1 2013 196
Dongwha Pharm Co., Ltd., H1 2013 197
Green Cross Corporation, H1 2013 198
Kukje Pharmaceutical Industry Co., Ltd., H1 2013 199

List of Figures

Number of Products under Development for Bacterial Infections, H1 2013 24
Products under Development for Bacterial Infections - Comparative Analysis, H1 2013 25
Products under Development by Companies, H1 2013 26
Products under Investigation by Universities/Institutes, H1 2013 49
Late Stage Products, H1 2013 56
Mid Clinical Stage Products, H1 2013 57
Early Clinical Stage Products, H1 2013 58
Discovery and Pre-Clinical Stage Products, H1 2013 59
Assessment by Monotherapy Products, H1 2013 354
Assessment by Combination Products, H1 2013 355
Assessment by Route of Administration, H1 2013 356
Assessment by Stage and Route of Administration, H1 2013 357
Assessment by Molecule Type, H1 2013 358
Assessment by Stage and Molecule Type, H1 2013 359

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.